INCHEON, South Korea — Celltrion, Inc. (KRX:068270) today announced that the U.S. Food and Drug Administration (FDA) has scheduled the Biologics License Application (BLA) for CT-P10, a proposed ...

Celltrion had completed the resubmission for the approval of CT-P10, a proposed biosimilar to Rituxan ® (rituximab) last month. In accordance with FDA regulations, the approval procedure will be ...

* Teva Pharmaceuticals and Celltrion Healthcare, in November 2019, stated that TRUXIMA (rituximab-abbs) injection is the first biosimilar to the reference product Rituxan1 (rituximab) now ...

The global rituximab biosimilars market is expected to decline from $1.84 billion in 2019 to $1.78 billion in 2020 at a compound annual growth rate (CAGR) of -3.22%. The decline is mainly due to ...

Celltrion-merger plan SEOUL, Aug. 16 (Yonhap) -- Celltrion Inc., a South Korean biopharmaceutical firm, said Friday it has decided not to merge with its chemical drug-producing affiliate ...

In February, Celltrion won public tenders for Truxima (rituximab) and Yuflyma (adalimumab).

Korean biopharmaceutical firm Celltrion said Tuesday it will spend around 75 billion won ($56.2 million) to buy back its shares as part of efforts to increase its shareholders' value.

Another biosimilar Rituxan, produced by Celltrion and Teva, was rejected by the FDA last month. Rituximab biosimilars both Celltrion and Novartis are already available in Europe and sales of Rituxan ...

Hikma now has exclusive agreements with Celltrion for three biosimilar products - Truxima™ (rituximab), Remsima® (infliximab) and Herzuma® (trastuzumab) - in all its MENA markets.